ReviewBone marrow transplantation2026
Fertility preservation in 2026: current landscape in Europe and the United States for children and adolescents undergoing hematopoietic stem cell transplantation-recommendations on behalf of the Westhafen Intercontinental Group.
Review in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Advances in hematopoietic stem cell transplantation (HSCT) and other cellular therapies have continued to improve the long-term outcomes for pediatric patients undergoing these treatments. However, treatment impacts on future fertility can have a substantial impact on the patient's quality of life. Concurrent with improvements in transplantation, fertility preservation (FP) options and outcomes have also evolved. Options such as ovarian tissue cryopreservation and testicular tissue cryopreservation are now more widely available and can be considered for very young patients. The timing and choice of FP to be offered can be complex, and many considerations must be made when counseling patients and families. Cost and access are also variable depending on the country and region in which a patient resides. The aim of this paper is to provide an updated overview of the current strategies and recommendations for FP that should be offered to all children and adolescents undergoing an allo-HSCT. By summarizing contemporary evidence and practices, this paper may provide support to clinicians in delivering equitable, informed, and accessible FP counseling and care for all eligible patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.